<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102669">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116660</url>
  </required_header>
  <id_info>
    <org_study_id>0518-284</org_study_id>
    <secondary_id>2013-001637-40</secondary_id>
    <nct_id>NCT02116660</nct_id>
  </id_info>
  <brief_title>Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)</brief_title>
  <acronym>RANIA</acronym>
  <official_title>Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study)(Phase 2b - Protocol No. MK-0518-284-01)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate changes in renal function, efficacy, and safety when switching from a
      combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r)
      to a combination of raltegravir (MK-0518) plus nevirapine plus lamivudine in human
      immunodeficiency virus (HIV)-1 participants with suppressed viremia and impaired renal
      function (MK-0518-284)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Renal Function</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Decline in Renal Function at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suppressed Viremia (&lt;50 copies/mL HIV-1 Ribonucleic Acid [RNA]) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Suppressed Viremia (&lt;50 copies/mL HIV-1 RNA) at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Decline in Renal Function at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir 400 mg oral twice daily plus nevirapine 200 mg oral twice daily plus lamivudine 150 mg oral twice daily for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir (MK-0518)</intervention_name>
    <description>Raltegravir (MK-0518) 400 mg tablets</description>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Nevirapine (NVP) 200 mg tablets</description>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine (3TC) 150 mg tablets</description>
    <arm_group_label>Raltegravir plus Nevirapine plus Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir disoproxil fumarate (TDF) 300 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>Emtricitabine (FTC) 200 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir</intervention_name>
    <description>Lopinavir (LPV) 200 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir (r) 100 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Atazanavir (ATV) 300 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir (DAR) 400 mg tablets</description>
    <arm_group_label>Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, or non-pregnant, non-breastfeeding female

          -  No previous history of virological failure

          -  No previous exposure to non-nucleoside reverse transcriptase inhibitors or integrase
             inhibitors

          -  No previous history of intolerance to lamivudine

          -  At least 2 documented plasma HIV-1 RNA &lt;50 copies/mL and no HIV-1 &gt;50 copies/mL in
             the 12 months before screening

          -  Receiving the same protease inhibitor/ritonavir plus tenofovir/emtricitabine
             combination for at least the 6 months before screening

          -  Has no major International Antiviral Society (IAS)-USA mutations on genotype testing
             performed before starting antiretroviral treatment

          -  Sexually-active participants and their partners of child-bearing potential agree to
             use a medically acceptable method of contraception from 2 weeks before Day 1 and for
             at least 6 months after the last dose of study drug (postmenopausal women are not
             required to use contraception; sexually-active male participants with a female
             partner of child-bearing potential must provide written informed consent to
             information regarding any pregnancy)

        Exclusion Criteria:

          -  Positive for hepatitis B surface antigen (HBsAg+) or anticipated need for hepatitis C
             virus treatment

          -  Liver cirrhosis

          -  Allergy or sensitivity to the investigational product or excipients

          -  Female participant who is nursing

          -  Female participant who is pregnant or intends to become pregnant

          -  Has an active Acquired Immunodeficiency Syndrome (AIDS)-defining event except stable
             Kaposi Sarcoma or HIV Wasting Syndrome

          -  Received any investigational drug within 30 days before screening

          -  Participated in any other clinical trial within 30 days before signing informed
             consent for the current trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
